Product news

Share this article:
Teva said the FDA approved its generic version of Procter & Gamble Actonel (risedronate sodium tablets) in 5 mg, 30 mg and 35 mg doses to treat and prevent postmenopausal and glucocorticoid-induced osteoporosis, and to treat Paget's disease. Actonel had US sales of about $1 billion, for the 12 months ended June 30, based on IMS sales data.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.